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BACKGROUND. Drugs and vaccines that can interrupt the transmission of Plasmodium
falciparum will be important for malaria control and elimination. However, models for early
clinical evaluation of candidate transmission-blocking interventions are currently
unavailable. Here, we describe a new model for evaluating malaria transmission from
humans to Anopheles mosquitoes using controlled human malaria infection (CHMI).
METHODS. Seventeen healthy malaria-naive volunteers underwent CHMI by intravenous
inoculation of P. falciparum–infected erythrocytes to initiate blood-stage infection. Seven to
eight days after inoculation, participants received piperaquine (480 mg) to attenuate asexual
parasite replication while allowing gametocytes to develop and mature. Primary end points
were development of gametocytemia, the transmissibility of gametocytes from humans to
mosquitoes, and the safety and tolerability of the CHMI transmission model. To investigate
in vivo gametocytocidal drug activity in this model, participants were either given an
experimental antimalarial, artefenomel (500 mg), or a known gametocytocidal drug,
primaquine (15 mg), or remained untreated during the period of gametocyte carriage.
RESULTS. Male and female gametocytes were detected in all participants, and
transmission to mosquitoes was achieved from 8 of 11 (73%) participants evaluated.
Compared with results in untreated controls (n = 7), primaquine […]
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Introduction
Considerable reductions in the global burden of malaria have 
been achieved in recent years, and this has led to a renewed focus 
on achieving malaria elimination and eventual eradication (1). 
However, progress is threatened by the spread of drug-resistant 
parasites and insecticide-resistant mosquitoes, and a major chal-
lenge to malaria control and elimination is interrupting the highly 
efficient process of transmission (2). Transmission of Plasmodium 
falciparum begins when a subset of asexual parasites commit to 
becoming either male or female gametocytes — the transmissible 
forms of the malaria parasite. Mature gametocytes then appear in 
circulation approximately 10 days later following gametocytogen-
esis, a process whereby the committed gametocytes sequester out 
of circulation as they develop and mature (3–5). Transmission can 
occur when these mature gametocytes are taken up in a mosquito 
blood meal and complete sporogonic development, rendering the 
mosquito infectious (4, 5). Novel approaches that reduce transmis-
sion, either by eliminating the gametocyte reservoir in the human 
host or by inhibiting development of malaria parasites within the 
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ual parasites (16–18) and the efficacy of 
blood-stage vaccines (19, 20). Recently, 
we have also demonstrated that female 
gametocytes may be observed during 
IBSM if permissive drugs are used (21, 
22). If both male and female gameto-
cytes (which are nonpathogenic) can be 
reproducibly induced in this model at 
densities high enough to infect mosqui-
toes, then a CHMI transmission model 
could fill a critical gap in the clinical 
development pipeline for TBIs.
Developing a P. falciparum CHMI 
transmission model is more complex 
than traditional CHMI studies that 
evaluate preerythrocytic or blood-stage 
interventions, as these studies are usu-
ally concluded before circulating game-
tocytes are detectable (~10 days after the 
first appearance of asexual parasites) 
(3–5). Since gametocytes develop from a 
subset of the asexual parasite population, in order for CHMI par-
ticipants to develop gametocytemia in this model, they must first 
develop an asexual parasite infection. Following gametocyte com-
mitment and initiation of gametocytogenesis, asexual parasite rep-
lication must then be attenuated using a drug that permits contin-
ued gametocyte development, such as piperaquine (21).
Here, we use IBSM to establish a P. falciparum CHMI model 
for evaluating transmission of malaria from humans to mosqui-
toes. We assess whether gametocytemia can be safely and repro-
ducibly induced in CHMI participants and the transmissibility of 
these gametocytes to mosquitoes. We also evaluate factors that 
may contribute to transmission success, including the relationship 
between asexual parasitemia and gametocyte burden, the sex ratio 
of male and female gametocytes, and the relationship between 
gametocyte density and mosquito infection rate. In addition, we 
assess the utility of this model for evaluating the in vivo gameto-
cytocidal activity of artefenomel (formerly known as OZ439), a 
promising synthetic trixolane in phase 2 clinical development that 
rapidly clears asexual parasitemia (17, 23).
Results
Seventeen malaria-naive volunteers were enrolled in 2 clini-
cal trials (Experimental Falciparum Transmission to Anopheles 
[EFITA], n = 6 and Effectiveness of OZ439 as a Gametocytocidal 
and Transmission Blocking Agent [OZGAM], n = 11), run in paral-
lel and undertaken as 3 sequential groups. Group 1 commenced 
in May 2015, group 2 in June 2016, and group 3 in August 2016 
(Supplemental Table 1; supplemental material available online 
with this article; https://doi.org/10.1172/JCI98012DS1). Baseline 
characteristics of the participants are presented in Table 1.
On day 0, the participants were experimentally infected with 
P. falciparum by intravenous administration of approximately 
2,800 parasitized red blood cells (pRBCs). On day 7 or 8 post 
inoculation (pi), asexual parasite replication was attenuated by 
treatment with a single oral dose of piperaquine (480 mg), and if 
a recrudescent infection developed, a single oral dose of pipera-
mosquito vector, are considered key for elimination (2). Timely 
development of such interventions will require a robust pipeline 
for discovery and evaluation.
Research into transmission-blocking interventions (TBIs) has 
accelerated in the last decade (2, 6). Preclinical assays and high-
throughput screens have been developed and refined and are 
proving useful for identifying new drug and vaccine candidates 
(7–9). How well these assays predict human in vivo transmission-
blocking efficacy has yet to be determined, making it challenging 
for researchers to select and prioritize the most promising candi-
dates for further development (6). The path for evaluating candi-
date TBIs beyond preclinical studies is also not well established 
and at present relies on efficacy testing in the field (6, 10). Pro-
posed trial designs in endemic populations include randomized 
trials to evaluate effect on gametocyte carriage and transmission 
to mosquitoes or cluster randomized trials to evaluate reduction 
in incident infections. Although extremely relevant, these types of 
studies are lengthy and difficult to implement due to the complex 
and changing nature of malaria transmission epidemiology (6, 11, 
12).Therefore, an in vivo model for early stage clinical evaluation 
of TBIs in malaria-naive volunteers would enable rapid and cost 
effective assessment of candidate drugs and vaccines before they 
are progressed to field studies.
Controlled human malaria infection (CHMI) with P. falci-
parum has been successfully used for early stage clinical evalu-
ation of drugs and vaccines targeting the preerythrocytic and 
blood-stage infection (13–15). CHMI can be initiated either by 
sporozoites via the bites of infected mosquitoes or injection of 
cryopreserved sporozoites or by induced blood-stage malaria 
(IBSM) infection, in which P. falciparum–infected erythrocytes 
are administered intravenously. IBSM offers an advantage over 
sporozoite-initiated CHMI studies when evaluating the blood 
stages of malaria in that all participants develop blood-stage para-
sitemia simultaneously, which simplifies trial design and conduct. 
P. falciparum IBSM studies have evaluated the pharmacokinetic 
and pharmacodynamic profile of candidate drugs targeting asex-
Table 1. Baseline characteristics of participants enrolled in the EFITA (n = 6) and OZGAM  
(n = 11) studies
EFITA OZGAM Total
Primaquine Artefenomel
(n = 6) (n = 5) (n = 6A) (n = 17)
Age (yr) 24 (20.2–28.7) 26 (23.0–31.5) 25 (21.5–34.7) 26 (21.5–28.5)
Sex (male) 2 (33.3%) 5 (100%) 6 (100%) 13 (76.5%)
Ethnic origin
 White 6 (100%) 5 (100%) 3 (50.0%) 14 (82.3%)
 Native Hawaiian or OPI 0 0 1 (16.7%) 1 (5.9%)
 Indian 0 0 1 (16.7%) 1 (5.9%)
 Latino 0 0 1 (16.7%) 1 (5.9%)
Height (cm) 169 (162.8–185.3) 176 (172.5–189.0) 178 (167.8–187.5) 176 (168.0–186.0)
Body weight (kg) 59.0 (53.0–86.4) 90.4 (73.1–96.0) 75.9 (69.1–82.0) 76.4 (59.0–88.7)
Body mass index (kg/m2) 20.7 (20.0–25.1) 27.1 (23.1–29.5) 24.2 (21.1–25.8) 24.3 (20.7–26.9)
Data are shown as n (%) or median (IQR). AIncludes 2 subjects who were not dosed with artefenomel. OPI, 
other Pacific islander.
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(2 treated on day 7 and 3 treated on day 
8), and following an initial decline in par-
asite densities, the remaining 12 partici-
pants developed recrudescent asexual 
infections. Recrudescence was cleared 
in all 12 participants with a single dose 
of piperaquine (960 mg) administered 
when required between day 10 and day 
24 pi. Recrudescence occurred in sub-
jects with varying levels of initial para-
sitemia, and development of recrudes-
cence was not related to parasite density 
at time of treatment.
Appearance of gametocytes in 
peripheral circulation was monitored 
by quantitative reverse-transcriptase 
PCR (qRT-PCR) for female-specific 
pfs25 mRNA (24) and male-specific 
Pf3D7_1469900 mRNA (hereafter 
referred to as pfMGET) (25). Both male 
and female gametocytes were detected 
in all participants and were first detect-
ed on day 10 pi. Female gametocyte 
densities peaked between day 20 and 
day 25 pi, while male gametocyte den-
sities peaked a day earlier, between day 
19 and day 24 pi (Figure 3, B and C). 
Delaying attenuation of asexual para-
site replication until day 8 resulted in a significant increase in the 
asexual parasitemia AUC (P = 0.006) and gametocytemia AUC (P 
= 0.04) (Figure 3, D and E), with no adverse effect on participant 
safety (see below). When data from all participants were analyzed, 
gametocytemia AUC significantly correlated with both the asexu-
al parasite levels on the day of treatment and the asexual parasit-
emia AUC prior to treatment (Spearman’s r = 0.83, P < 0.0001 and 
Spearman’s r = 0.87, P < 0.0001, respectively) (Figure 3, F and G).
Gametocyte density ranged from 243 to 6,888 gametocytes/ml 
at peak gametocytemia, and as observed in natural infections, there 
was a strong female gametocyte bias (Figure 4A and refs. 5, 12). 
The average male to female gametocyte ratios from 3 participants 
who did not experience recrudescence and did not receive game-
tocytocidal intervention were 0.25, 0.29, and 0.22, with an overall 
mean ratio of 0.25 (range: 0.15–0.55), meaning an average of 1 male 
to 4 female gametocytes. Some variation in male to female ratio 
occurred over the course of gametocytemia, but this did not trend 
to becoming more male or female biased over time (Figure 4B).
Asexual parasites were quantified throughout the study using 
18S rDNA qPCR; however, this assay detects all circulating asexual 
parasites and gametocytes, making it difficult to distinguish recru-
descent asexual infections from gametocytemia. We therefore 
measured skeleton binding protein-1 (SBP-1) mRNA transcripts 
— which are abundantly expressed in ring-stage parasites — to 
detect asexual parasite recrudescence (26, 27). As expected, prior 
to initial piperaquine treatment, the level of ring-stage parasit-
emia detected by the SBP-1 mRNA assay closely matched the total 
parasite levels measured by 18S rDNA qPCR (Figure 5, A–D, and 
Supplemental Figure 1, A–C). Following asexual parasite clear-
quine (960 mg) was administered. Development of gametocy-
temia was monitored in all participants and, once detected, the 
transmissibility of gametocytes to mosquitoes was assessed via 
mosquito-feeding assays (Figures 1 and 2). To investigate the abil-
ity of drugs to clear gametocytes and/or prevent transmission, 5 
participants received a single oral dose of primaquine (15 mg), a 
known gametocytocidal drug, 4 participants received the experi-
mental antimalarial artefenomel (500 mg), and 8 participants 
served as negative controls and were untreated during the period 
of gametocyte carriage. Changes in gametocytemia between the 
day of drug treatment and 5 days after treatment were evalu-
ated using 18S rDNA quantitative PCR (qPCR) in samples where 
asexual parasites were not present. One participant in the nega-
tive control group had asexual parasitemia during this period and 
was therefore excluded from analysis. At the end of the study, all 
participants received a course of artemether/lumefantrine and, if 
required, a single dose of primaquine (45 mg) to clear all remain-
ing parasites (as detailed in Supplemental Table 1).
P. falciparum parasites were detected by 18S rDNA qPCR in 11 
of 17 participants on day 4 pi and were detected in all participants 
on day 5 pi. Piperaquine (480 mg) was administered to attenuate 
asexual parasite replication on day 7 pi for group 1. This treatment 
was delayed until day 8 pi for groups 2 and 3 (following review of 
safety data and approval from the Safety Monitoring Committee, 
CNS Pty. Ltd.) in order to maximize the biomass of asexual para-
sites with potential to commit to gametocytogenesis. The initial 
pattern of parasite growth did not vary between the groups who 
received piperaquine on day 7 or day 8 (Figure 3A). Piperaquine 
(480 mg) completely cleared asexual parasitemia in 5 participants 
Figure 1. Study design schematic. Malaria-naive volunteers (n = 17) were inoculated with pRBCs on day 
0 (D0). Blood samples were taken for PCR analysis to measure both asexual parasites and gametocytes 
from day 4 pi and continued until the end of the study. Piperaquine (PIP 480 mg) treatment was admin-
istered on either day 7 or day 8 pi, and any subsequent recrudescent asexual infections were treated 
with piperaquine (PIP 960 mg). Mosquito-feeding assays were performed between day 17 and day 30 pi 
by feeding mosquitoes by live bite (direct skin feeding) on the participants or by membrane feeding on 
venous blood (Aim 1). During the period of gametocyte carriage, participants either received primaquine 
(15 mg) or artefenomel (500 mg) or did not receive either intervention (Aim 2). All participants received 
a course of artemether/lumefantrine and, if required, a single dose of primaquine (45 mg) to clear all 
parasites at the end of the study (Supplemental Table 1).
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cytocidal intervention (until end of study drug was administered) 
(Figure 5, A–D, and Supplemental Figure 1, A–C).
The infectivity of gametocytes to Anopheles stephensi mosqui-
toes was evaluated in the participants who received piperaquine 
(480 mg) treatment on day 8 pi (n = 11). Successful transmission 
of malaria to mosquitoes was achieved from 8 of 11 participants 
(73%) at least once between day 17 and day 30 pi using direct 
ance, SBP-1 mRNA was undetectable during the period of game-
tocyte carriage until recrudescent asexual infections developed 
(Figure 5A and Supplemental Figure 1, A–C). The course of game-
tocytemia was not affected by treating recrudescent infections 
with piperaquine (960 mg) (Figure 5A and Supplemental Figure 1, 
A–C), and gametocyte levels remained stable (>100 gametocytes/
ml) for up to 21 days in participants who did not receive gameto-
Figure 2. Trial profile. All participants received 480 mg piperaquine. Twelve participants also received 960 mg piperaquine to treat recrudescence. iMosqui-
to infectivity not assessed in cohort 1 (n = 6). iiAll 6 participants in the EFITA study were not intended to be randomized and 4 participants in the OZGAM 
study were not randomized due to recruitment and drug availability limitations (as detailed in Methods). iiiAll 6 participants from EFITA and 2 from OZGAM 
did not receive any drug during the period of gametocyte carriage (Supplemental Table 1).
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sistent across feeding assays (Table 4), with mosquito infection 
rates increasing with the level of gametocytemia (Poisson’s regres-
sion, likelihood ratio [L-R χ2 = 36.4, P < 0.0001]) (Supplemental 
Figure 2). Concentration of parasite-infected erythrocytes over 
a Percoll gradient resulted in a pronounced increase in mosquito 
infection rate. On 3 occasions, blood pooled from all participants 
was enriched via Percoll and resulted in 36%, 31%, and 50% prev-
alence of mosquito infection. In this experiment, equivalent pro-
portions of mosquitoes were infected with either oocysts on day 
9 after feeding (31%, 16/51) or salivary gland sporozoites on day 
14 after feeding (29%, 12/41), demonstrating the oocysts complete 
development to the mosquito stage (Supplemental Table 4 and 
Supplemental Figure 3D).
Primaquine (15 mg) treatment resulted in 90% reduction in 
gametocyte density when measured 5 days after treatment, com-
pared with 21% in the group receiving artefenomel (500 mg) and 
22% in the group that received no intervention. The difference 
between the primaquine (15 mg) group and both the negative con-
trol group and the artefenomel group was significant (P = 0.01 and 
P = 0.04, respectively), but not that between the artefenomel group 
and the negative control group (Figure 7B). As polymorphisms in 
the CYP2D6 gene may reduce the efficacy of primaquine against 
gametocytes, genotyping of the coding gene sequence was per-
formed as previously described (refs. 21, 28 and Supplemental 
skin-feeding assays (DFA), direct membrane-feeding assays on 
venous whole blood (DMFA), or membrane-feeding assays with 
serum replacement (MFA SR). Transmission occurred on all 
days evaluated except days 17 and 29, with no trend in chang-
ing infectivity over time (Figure 6, A and B). In assays in which 
transmission occurred, the mosquito infection rate ranged from 
2% to 17%, with a median of 7% for DFAs (n = 18), 4% for DMFAs 
(n = 18), and 6% for MFA SR (n = 14) (Table 2 and Supplemen-
tal Tables 2 and 3). Paired analysis was performed on a subset of 
samples to compare the transmission efficiency with the differ-
ent feeding assays. Mosquito infection rates were approximately 
7-fold higher (P = 0.0004, n = 20) with DFAs (median 7%; inter-
quartile range [IQR] 3.3–9.2) compared with DMFAs (median 
1%; IQR 0–3.4) and approximately 3-fold higher (P = 0.001, n = 
14) with MFA SR (median 6%; IQR 4–10) compared with DMFA 
(median 2%; IQR 0–2.5) (Table 3).
The infectivity of participants varied, with 3 participants not 
transmitting to mosquitoes at any time during the study. Partici-
pants who were noninfectious had significantly lower levels of 
circulating gametocytes (range: 243–941 gametocytes/ml) than 
those who were infectious (range: 1,589–6,888 gametocytes/ml) 
when peak gametocytemia was compared (P = 0.01) (Figure 7A). 
The median gametocytemia at the time of the mosquito feeding 
assay was also greater in the infectious samples, and this was con-
Figure 3. Development of parasitemia and gametocytemia. Participants (n = 17) were experimentally infected with P. falciparum on day 0. (A) Parasite 
development as measured by 18S rDNA qPCR. Piperaquine (480 mg) was administered on day 7 pi for group 1 (n = 6; vertical red dashed line) or on day 8 pi 
for groups 2 and 3 (n = 11; vertical gray dashed line). Gametocyte development measured by qRT-PCR for (B) pfs25 (female gametocytes) and (C) pfMGET 
(male gametocytes). For A–C, the thin lines show individual participant curves and geometric means are in bold. (D) Asexual parasitemia AUC (days 0–10) 
and (E) gametocytemia AUC (days 10–21), grouped by treatment day (480 mg piperaquine) (compared by Kolmogorov-Smirnov test). Correlation of game-
tocytemia AUC (from day 10–21) with (F) asexual parasitemia on the day of treatment or (G) asexual parasitemia AUC (from day 0 to day of treatment) 
assessed using Spearman’s rank correlation.
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Table 5). However, there was no relationship between the CYP2D6 
genotype and observed primaquine activity.
Transmission prevalence was too low to evaluate the abil-
ity of the drugs to inhibit mosquito-stage parasite development 
using DFAs, DMFAs, or MFA SR. However, a pilot experiment in 
which gametocytes were enriched via Percoll prior to membrane 
feeding demonstrated that with high enough gametocyte densi-
ties, it may be possible to detect reductions in mosquito-stage 
parasite development in this CHMI transmission model. Using 
enriched gametocytes in the membrane-feeding assay, transmis-
sion occurred in 2 of 2 participants (prevalence of infection of 4% 
and 52%) prior to primaquine (15 mg) treatment and in 0 of 2 par-
ticipants after treatment. In contrast, transmission occurred with 
enriched gametocytes at both the before and after drug treatment 
time points for 2 participants who did not receive any interven-
tion (Supplemental Table 6).
This CHMI transmission model was safe and well tolerated; 
all participants completed their 3 scheduled direct skin feeds, and 
the number and severity of adverse events (AEs) did not increase 
by delaying treatment of initial asexual parasitemia from day 7 
to day 8 pi (Figure 8). From a total of 205 AEs, 132 (64.4%) were 
assessed as probably or possibly related to malaria, 13 (6.3%) were 
probably or possibly related to piperaquine, 2 were possibly asso-
ciated with artefenomel, and none were related to artemether/
lumefantrine or primaquine. Fourteen (6.8%) AEs were attributed 
to direct skin feeding, and the remaining AEs were attributed to 
other causes. The most common AE associated with malaria was 
headache (39 cases across 13 participants). The AEs were most-
ly mild (n = 163; 79.5%) or moderate (n = 39; 19.0%) in severity, 
with no serious AEs recorded (Supplemental Tables 7–9). Three 
AEs were assessed as severe and were attributed to malaria infec-
tion. These were fatigue, elevated alanine aminotransferase (ALT) 
(peak 9.2 × upper limit of normal [ULN]), and elevated aspartate 
aminotransferase (AST) (peak 5.7 × ULN). Both severe (>5 × ULN) 
liver transaminase elevations were experienced by the same par-
ticipant, who did not receive artefenomel. An additional partici-
pant also developed a moderate ALT elevation (≤5 × ULN). Nei-
ther participant developed symptomatic hepatitis or significant 
elevation of bilirubin; therefore, Hy’s law was not reached (29). All 
liver transaminase elevations were transient and asymptomatic 
and returned to within normal ranges by the end of the study with 
no intervention. Similar asymptomatic ALT and AST elevations 
with unchanged bilirubin have been reported in other CHMI stud-
ies and are believed to be secondary to malaria infection (16, 30).
Discussion
We have demonstrated, for what we believe is the first time, the 
safe and reproducible induction of P. falciparum gametocytes in 
CHMI study participants at densities infectious to mosquitoes, 
thereby demonstrating the potential for evaluating TBIs in this 
model. This was achieved by intravenously administering P. falci-
parum–infected erythrocytes to healthy, malaria-naive volunteers 
and treating the resulting asexual parasitemia with low dose piper-
aquine; this permitted gametocyte development. Using recently 
defined sex-specific mRNA markers (24, 25), we quantified the 
circulating gametocyte densities by qRT-PCR and detected both 
male and female gametocytes in all participants. Gametocytes 
were first detected 10 days after inoculation, suggesting asexual 
parasites commit to gametocytogenesis from the first wave of 
parasitemia, and the level of gametocytemia was strongly associ-
ated with the preceding asexual parasite biomass. We were able 
to significantly increase the level of gametocytemia by delaying 
initial treatment of parasitemia by 24 hours (P = 0.04), thus maxi-
mizing the asexual parasite burden without any adverse effect 
on participant safety. Measurement of SBP-1 mRNA transcripts 
allowed us to accurately distinguish recrudescent asexual parasit-
emia from gametocyte appearance during the study, thus enabling 
timely treatment and clearance of recrudescent infections, ensur-
ing participant safety. Female gametocytes were present in higher 
numbers than male gametocytes, with an average gametocyte sex 
ratio of 1 male to 4 female gametocytes. This female-biased game-
tocyte sex ratio is also found in natural infections that transmit 
Figure 4. Male and female gametocyte sex ratios. Gametocyte development was monitored by qRT-PCR for pfs25 (female gametocytes) and pfMGET 
(male gametocytes). (A) Comparison of male and female gametocyte densities over time, with box plots indicating the median and whiskers showing the 
minimum and maximum responses (only includes data at time points where values exist for > 50% of the participants). (B) Proportion of gametocytes 
that are either male or female over time for 3 participants.
The Journal of Clinical Investigation   C L I N I C A L  M E D I C I N E
1 5 5 7jci.org   Volume 128   Number 4   April 2018
efficiently to mosquitoes, suggesting gametocytes in our model 
are present at transmissible sex ratios (5, 12). Gametocytemia was 
stable (>100 gametocytes/ml) for up to 21 days, and gametocyte 
densities ranged from 243 to 6,888 gametocytes/ml at peak game-
tocytemia. Primaquine (15 mg) treatment significantly reduced 
gametocyte densities compared with those in participants receiv-
ing no drug (P < 0.01) or those receiving the experimental anti-
malarial artefenomel (500 mg) (P = 0.04), demonstrating that this 
model can be used to evaluate gametocyte clearance activity.
Gametocytes were transmissible from the majority of par-
ticipants (8/11, 73%) to laboratory-reared An. stephensi mosqui-
toes using both skin-feeding and membrane-feeding assays. We 
observed mosquito infection rates between 2% and 17%, which is 
comparable to the rate of mosquito infection observed from natu-
ral gametocyte carriers, where gametocyte densities between 1 
and 25 gametocytes/μl have been reported to result in an average 
of 14% mosquito infection (31). During natural infection, there is 
also a positive association between gametocyte density and trans-
mission success, and in our model, we observed a similar increase 
in mosquito infection rate with increasing gametocytemia (11, 31–
33). We also found that participants whose peak gametocytemia 
was below 1,000 gametocytes/ml were not infectious to mosqui-
toes at any time during the study. This suggests that, below this 
threshold of gametocyte density, the likelihood of mosquito infec-
tion is minimal due to the low probability of a mosquito taking up 
both a male and a female gametocyte in a blood meal. Enhanced 
levels of transmission were achieved following the enrichment of 
gametocytes prior to membrane feeding, further supporting the 
association between gametocyte density and transmission suc-
cess. With these higher levels of transmission, we also confirmed 
the midgut oocyst infections were viable and able to complete 
mosquito-stage development, producing detectable salivary gland 
sporozoite infections.
Mosquito infection rates were higher via the natural route of 
infection compared with feeding mosquitoes on whole blood via a 
membrane. This is in accordance with previous studies and could 
be due to a number of reasons (12, 31). More gametocytes may be 
taken up by skin feeding due to gametocytes preferentially local-
izing to subdermal capillaries, or the optimal biological conditions 
for efficient transmission present in the microvasculature might 
Figure 5. The course of asexual parasitemia and gametocytemia. Representative graphs from groups 2 and 3 showing all data from qRT-PCR mRNA 
assays to illustrate the relationship between the parasite populations and the ability of SBP-1 mRNA to identify recrudescent infections. (A) Data from 
participant 203, (B) participant 306, (C) participant 302, and (D) participant 301 are shown. Male gametocytes (blue squares), female gametocytes (red 
circles), and ring-stage parasites (black triangles) are shown. Total parasitemia was also quantified by 18S rDNA qPCR (gray lines). Treatment administra-
tion is indicated with black arrows as follows: PIP 480, 480 mg piperaquine; PIP 960, 960 mg piperaquine; A/L, artemether/lumefantrine; PQ 45, 45 mg 
primaquine. Complete set of graphs for all participants is shown in Supplemental Figure 1, A–C.
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of participants. Once this level of gametocytemia is known, the 
model can be optimized to further increase levels of transmission. 
This could potentially be achieved using different parasite strains 
and/or vector mosquito combinations. Gametocyte production 
rates vary considerably among parasite lines, as does the suscep-
tibility of different An. stephensi species to P. falciparum infection 
(35). Moreover, parasite lines such as 3D7 and NF54 that are gen-
erally used in CHMI studies have been in laboratory culture for 
prolonged periods and may have reduced gametocyte-producing 
potential. It is therefore possible that gametocytes from these par-
asite lines and gametocytes present during natural infections may 
exhibit different transmission characteristics. Thus, investigating 
the gametocyte-producing potential of different parasite strains 
(both laboratory adapted and recent field isolates) and their infec-
tivity to different vectors represents an attractive approach for 
increasing gametocytemia in this model.
In conclusion, we have demonstrated that gametocytes can 
be safely and reproducibly induced in CHMI study participants 
and transmitted to mosquitoes in a system that is fully amenable 
to further optimization. This model can now be used for early 
clinical evaluation of promising drug candidates against mature 
circulating gametocytes in humans, and further optimization 
will enable testing of a broader range of TBIs. Furthermore, this 
model can be exploited to better understand the dynamics and 
not be replicated sufficiently in a membrane feed assay. Alterna-
tively, a component of the venous blood sample not present in vivo 
during skin feeding may inhibit transmission, such as the anticoag-
ulant (34). This hypothesis may also explain why we observed high-
er mosquito infection rates from membrane feeding with serum 
replacement compared with membrane feeding on whole blood. 
Removing the plasma from the whole blood sample may have 
removed or diluted the anticoagulant. Our model provides a new 
platform for these observations, as well as other factors governing 
efficient transmission, to be fully evaluated in a controlled setting.
This exploratory study was designed to investigate the poten-
tial to achieve transmission from humans to mosquitoes during 
CHMI; as this was an exploratory study, participant numbers were 
small. A clinical trial with a larger number of participants would be 
required to validate our observations and fully investigate variabil-
ity in challenge-study participants. Females were excluded from 
cohorts 2 and 3 due to a change in the safety requirements related 
to artefenomel, and this resulted in an unavoidable male bias in 
the overall study. Participant numbers in the treatment arms were 
lower than planned due to recruitment limitations and the unavail-
ability of artefenomel for group 3 participants. These factors, com-
bined with the low levels of transmission, reduced the statistical 
power when evaluating the ability of artefenomel to interfere with 
mosquito-stage parasite development. However, we were able to 
demonstrate with a reference gametocytocidal drug and enriched 
gametocytes that it is possible to detect a reduction in transmis-
sion to mosquitoes when gametocyte density is sufficiently high.
The levels of gametocytemia achieved in this study are prob-
ably too low for efficient evaluation of interventions designed to 
interfere with mosquito-stage parasite development. However, 
these data can be used to model the within-host gametocyte kinet-
ics and transmission dynamics. This information can be used to 
establish the appropriate sample size and sampling frequency 
required to fully characterize gametocytocidal and transmission-
blocking activity in this current model. Modeling these data would 
also allow us to determine the level of gametocytemia required to 
power these studies effectively with the necessarily small numbers 
Table 2. Mosquito infection rate
Rate of mosquito infection for all positive feeding assays (% of mosquitoes 
infected)
DFA DMFA MFA SR All feeding assays
n = 18 n = 18 n = 14 n = 50
7% 4% 6% 4%
(3.3–10.8) (3.3–7.2) (4.0–10) (3.3–7.2)
Median (IQR). Mosquito infection rate for assays where transmission 
occurred (positive feeding assays).
Figure 6. Infectivity to mosquitoes. Successful transmission is defined as the presence of oocysts in the mosquito midgut on day 8 or 9 after feeding 
as determined by 18S rDNA qPCR. Mosquito infection rate is reported as the prevalence of infection (percentage of mosquitoes infected per assay). (A) 
Prevalence of mosquito infection in all feeding assays performed for each participant in groups 2 and 3. (B) Prevalence of mosquito infection for all assays 
at each time point (dots represent the median, with error bars indicating the range) (Supplemental Tables 2 and 3).
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artefenomel in this model. Primary end points were transmissibility of 
gametocytes from humans to mosquitoes using direct and membrane-
feeding assays and the safety and tolerability of the CHMI transmis-
sion model. Successful transmission was defined as at least 1 oocyst-
positive mosquito per feeding assay, as measured by 18S rDNA qPCR. 
Gametocytocidal and transmission-blocking activity were defined as 
reduction in gametocyte densities as measured by PCR and a reduc-
tion in mosquito infectivity. Safety end point measures were frequency 
and severity of AEs, and results of clinical laboratory data (hematol-
ogy, biochemistry, serology, and urinalysis), physical examinations, 
vital sign assessments, and ECGs.
Procedures. All participants were inoculated by IBSM with approx-
imately 2,800 P. falciparum–infected human erythrocytes adminis-
tered intravenously as previously described (36) and monitored via 
daily telephone calls for AEs and malaria. Parasitemia was measured 
daily from day 4 pi, using a previously described qPCR assay targeting 
DNA from the 18S ribosomal RNA gene (rDNA) and twice daily once 
participants were confirmed as malaria positive (Supplemental Meth-
ods) (37). Asexual parasitemia was also measured with a qRT-PCR 
assay that measures SBP-1 mRNA transcripts (Supplemental Methods, 
Supplemental Table 10, and Supplemental Figure 4) (22, 26). To atten-
uate asexual parasite replication, participants were admitted for 48 
hours confinement and given 480 mg piperaquine phosphate (Penn 
biology of P. falciparum transmission, a critical consideration for 
malaria elimination agendas.
Methods
Study design and participants. EFITA (phase 1) and OZGAM (phase 1b) 
were single-center, open-label clinical trials run concurrently between 
April 30, 2015, and November 10, 2016, at the contract research orga-
nization Q-Pharm Pty. Ltd. Both protocols are provided in the Supple-
mental Methods. Participants were healthy, malaria-naive adults with 
normal vital signs and ECG results at baseline, aged between 18 and 
55 years, not living alone, and available for the duration of the study. 
Female participants were included in cohort 1, but were excluded from 
subsequent cohorts due to a change in the safety requirements related 
to artefenomel. Participants met all inclusion criteria and none of the 
exclusion criteria listed in the Supplemental Methods.
Randomization. The phase 1 study (EFITA) was designed for 6 par-
ticipants who would not receive any drug exploring gametocytocidal 
activity and was therefore not randomized. These participants would 
serve as negative controls for the phase 1b study (OZGAM). OZGAM 
was designed to investigate gametocytocidal drug activity with 12 par-
ticipants; 6 would receive the experimental antimalarial artefenomel 
(500 mg; formerly known as OZ439), and 6 would receive the posi-
tive control drug, primaquine (15 mg). The study was undertaken as 3 
sequential groups, and each group included participants from both stud-
ies in cohorts that were conducted concurrently (Supplemental Table 1).
Participants in OZGAM were to be randomized within their 
cohorts at a 1:1 ratio to the experimental or the positive control 
arm. Randomization occurred as planned for OZGAM cohort 1 par-
ticipants; however, the randomization schedule was abandoned for 
OZGAM cohort 2 because of recruitment limitations. OZGAM cohort 
2 was divided into cohort 2a (allocated to receive artefenomel) and 
cohort 2b (allocated to receive primaquine), and the 2 cohorts were 
conducted separately. OZGAM cohort 3 participants were random-
ized to receive artefenomel or primaquine, but none could be dosed 
with artefenomel due to an issue that arose with drug availability. Ran-
domization was completed by Q-Pharm Pty. Ltd. in blocks of 2 with a 
list prepared using the blockrand package in R (version 3.1.1).
Outcomes. The objectives of this study were to develop a CHMI 
model for evaluating human to mosquito transmission of malaria and 
to assess the gametocytocidal and transmission-blocking activity of 
Table 3. Mosquito infection rate using different feeding assays
Paired analysis of mosquito infection rate using different assays (% of mosquitoes 
infected)
DFA DMFA MFA SR P value
DFA vs. DMFA n = 20 n = 20 –
7% 1% – P = 0.0004
(3.3–9.2) (0.0–3.4)
DMFA vs. MFA SR – n = 14 n = 14
2% 6% P = 0.001
– (0.0–2.5) (4.0–10.0)
Median (IQR) or P value. Paired analysis of the mosquito infection rate 
when comparing 2 types of feeding assays. Groups compared using 
Wilcoxon’s matched-pairs signed rank test.
Figure 7. Gametocyte infectivity and clearance. (A) The peak 
gametocytemia (male and female gametocytes) for participants 
who were noninfectious throughout the study compared with 
participants who were infectious on at least one occasion. Box 
plots indicate the median and whiskers show the minimum and 
maximum responses. Groups compared using Mann-Whitney U 
test. (B) Percentage reduction in gametocytemia (as measured by 
18S rDNA qPCR in samples where ring-stage parasites were not 
present) between day of drug treatment and 5 days after treat-
ment with 15 mg primaquine (n = 5), 500 mg artefenomel  
(n = 4), or no drug (negative control, n = 7). One participant from 
the negative control group is not represented due to the presence 
of ring-stage parasites precluding analysis of gametocyte clear-
ance. Lines indicate the median response and groups compared 
by Kruskal-Wallis test with Dunn’s multiple comparison test 
comparing all groups.
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clear gametocytes (Supplemental Table 1 and Supplemental Table 13). 
End of study visits were on day 34 (group 1) or day 36 pi (groups 2 and 
3); however, participants were followed up until all outstanding abnor-
mal laboratory test results resolved (Supplemental Table 1).
Sample size and data analysis. The EFITA study was designed to 
assess infectivity of gametocytes to mosquitoes. As such, the sample 
size was not powered for clinical end points, but to explore mosquito 
infectivity. For OZGAM, to investigate the activity of artefenomel, 
sample size and power calculations were undertaken using data from 
a previous study (21). The outcome variable used was the slope of the 
gametocytemia decay curve; variance estimate was 0.039918 at a 5% 
2-tailed significance level and power of 80%. A range of effect sizes 
for the critical difference between treatment allocations was used to 
check sensitivity. For an effect size of 0.4, the required sample size per 
Pharmaceuticals) on day 7 pi (group 1) or day 8 pi (groups 2 and 3). After 
confinement, participants were monitored for up to 24 days and a sec-
ond dose of piperaquine phosphate (960 mg) was administered to par-
ticipants who experienced recrudescence. Gametocyte development 
was measured from day 7 pi by qRT-PCR for female-specific pfs25 
mRNA and male-specific pfMGET mRNA (Pf3D7_1469900) (Supple-
mental Methods) (24, 25). To determine infectivity of gametocytes to 
An. stephensi mosquitoes, feeding assays were performed on group 2 
and 3 participants between day 17 and day 30 pi via either direct skin 
feeding (~30 mosquitoes per assay, 3 assays per participant) or mem-
brane feeding (~50 mosquitoes per assay). Membrane-feeding assays 
were performed either with whole venous blood (direct membrane-
feeding assay; n = 6 per participant) or after removing the participant’s 
plasma and replacing with control serum prior to feeding (membrane 
feeding with serum replacement) (Supplemental Methods). 
Prior to performing the mosquito feeding assays, the mosquito 
colony was verified as being highly susceptible to P. falciparum 
infection using in vitro–cultured gametocytes (Supplemental 
Figure 3, A and B). The mosquitoes used in all experiments 
were healthy and fed well on the gametocytemic blood, with 
an average adult mosquito mortality of 7.6% and an average 
mosquito blood feeding rate of 97.4% (Supplemental Tables 
11 and 12). Transmission to mosquitoes was determined by 
detecting midgut oocysts using the 18S rDNA qPCR assay, 
with visual confirmation of oocysts performed by microscopy 
on a small random selection of midguts prior to PCR analy-
sis (Supplemental Methods and Supplemental Figure 3C). To 
investigate gametocytocidal drug activity, all 6 participants in 
the EFITA study and 2 participants in the OZGAM study were 
negative controls who received no investigational drug other 
than piperaquine. The remaining participants received arte-
fenomel (500 mg, n = 4) or primaquine (15 mg, n = 5) on day 
22 (group 1), day 25 (group 2), or day 24 (group 3) pi. At the end 
of the study, all participants received a course of artemether/
lumefantrine (Riamet, Novartis Pharmaceuticals Australia 
Pty. Ltd.; 4 tablets taken as a single dose every 12 hours for 60 
hours) and, if required, a single dose of 45 mg of primaquine to 
Table 4. Gametocytemia of infectious samples
Gametocytemia (gametocytes/ml)
Infectious samples Noninfectious samples Infectious vs. 
noninfectious samples
Median (IQR) Median (IQR) P value
DFA n = 18 n = 15
2,863 850 P < 0.0001
(1,971–3,470) (243–1,324)
DMFA n = 18 n = 48
2,311 949 P = 0.0005
(1,462–3,150) (210–2,344)
MFA SR n = 14 n = 8
1,670 741 P = 0.0038
(1,455–2,956) (279–998)
All feeding assays n = 50 n = 71
2,663 868 P < 0.0001
(1,481–3,150) (243–1,991)
Median (IQR) or P value. Comparison of the gametocytemia (total male and female 
gametocytes/ml) of samples that were infectious vs. noninfectious, displayed by 
feeding assay. Groups compared using Mann-Whitney U test.
Figure 8. Safety of experimental malaria infection. (A) Number and severity of AEs per participant with 480 mg piperaquine treatment on either day 7 pi 
(n = 6) or day 8 pi (n = 11). (B) Comparison of the number and severity of AEs by treatment day. Box plots indicate the median with whiskers showing the 
minimum and maximum responses. Groups compared using Mann-Whitney U test.
The Journal of Clinical Investigation   C L I N I C A L  M E D I C I N E
1 5 6 1jci.org   Volume 128   Number 4   April 2018
interpretation. KAC, MA, HM, MR, and CYTW performed experi-
ments. KAC analyzed data. KAC wrote the manuscript. All authors 
reviewed the manuscript.
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group was 6. It was therefore intended that 18 participants (EFITA, 
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tive control = 5, experimental = 4).
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parasite development within the mosquitoes and therefore precluded 
meaningful evaluation of infectivity in these experiments. Transmis-
sion data from group 1 were therefore excluded from analysis. Follow-
ing establishment of a new mosquito colony and optimization of the 
mosquito-rearing process, data from the 11 participants in groups 2 
and 3 were evaluated and reported. Samples collected on day 22 pi in 
group 1 (n = 6) and analyzed by qRT-PCR for mRNA transcripts did not 
meet quality control requirements and were excluded from analysis.
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comparing 2 groups of unpaired samples, the Mann-Whitney U test or 
the Kolmogorov-Smirnov test was used (all comparisons were on non-
parametric data). Two or more groups of nonparametric data were com-
pared by the Kruskal-Wallis test with Dunn’s multiple comparison test. 
For comparison of paired samples, Wilcoxon’s matched-pairs signed 
rank test was used for nonparametric data. Correlations were assessed 
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